Method Development and Validation for the Simultaneous Determination of Fexofenadine Hydrochloride and Montelukast Sodium in Drug Formulation Using Normal Phase High-Performance Thin-Layer Chromatography

<table>Densitogram of formulation containing 7200 ng spot<sup>−1</sup> of FEX (<svg height="16.2875" id="M50" style="vertical-align:-4.77652pt" version="1.1" viewbox="0 0 19.700001 16.2875" width="19.700001" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,16.2875)">
<g transform="translate(72,-58.97)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑅</tspan>
</text>
<text transform="matrix(1,0,0,-1,-62.7,60.66)">
<tspan style="font-size: 8.75px; " x="0" y="0">𝑓</tspan>
</text>
</g>
</g>
</svg> 0.21) and 600 ng spot<sup>−1</sup> of MTKT (<svg height="16.2875" id="M51" style="vertical-align:-4.77652pt" version="1.1" viewbox="0 0 19.700001 16.2875" width="19.700001" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,16.2875)">
<g transform="translate(72,-58.97)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑅</tspan>
</text>
<text transform="matrix(1,0,0,-1,-62.7,60.66)">
<tspan style="font-size: 8.75px; " x="0" y="0">𝑓</tspan>
</text>
</g>
</g>
</svg> 0.59).</table>

International Scholarly Research Notices

fig6

Figure 6

Figure 6: Method Development and Validation for the Simultaneous Determination of Fexofenadine Hydrochloride and Montelukast Sodium in Drug Formulation Using Normal Phase High-Performance Thin-Layer Chromatography 

Figure 6 | Method Development and Validation for the Simultaneous Determination of Fexofenadine Hydrochloride and Montelukast Sodium in Drug Formulation Using Normal Phase High-Performance Thin-Layer Chromatography 